Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population

American Journal of Hematology

Volumn 86, Issue 2, 2011, Pages 163-169

  Lv, Ling ^a   Lin, Guowei ^a   Gao, Xiang ^a   Wu, Cuie ^b   Dai, Junmin ^b   Yang, Yongchen ^c   Zou, Hejian ^a   Sun, Hengjuan ^c   Gu, Minghua ^a   Chen, Xi ^d   Fu, Hua ^b   Bao, Liming ^c,e  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI CHILDREN S HOSPITAL   (China)

^d CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENE; GASOLINE; HAIR DYE; HERBICIDE; PESTICIDE; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; BUILDING; CANCER RISK; CHINA; CHINESE MEDICINE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENVIRONMENTAL FACTOR; FEMALE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; OCCUPATIONAL EXPOSURE; POPULATION RESEARCH; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; TRADITIONAL MEDICINE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; CHINA; DRUGS, CHINESE HERBAL; EDUCATIONAL STATUS; FEMALE; HAIR DYES; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OCCUPATIONAL EXPOSURE; PANCYTOPENIA; RISK FACTORS; SMOKING; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 78851471291     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21941     Document Type: Article

References (48)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
2. Jaffe ES, Harris N, Stein H, et al. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press; Lyon 2001.
3. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
4. Nisse C, Haguenoer JM, Grandbastien B, et al. Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France. Br J Haematol 2001; 112: 927-935.
5. Ma X, Lim U, Park Y, et al. Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort. Am J Epidemiol 2009; 169: 1492-1499.
6. Nagata C, Shimizu H, Hirashima K, et al. Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome. Leuk Res 1999; 23: 57-62.
7. Strom SS, Gu Y, Gruschkus SK, et al. Risk factors of myelodysplastic syndromes: A case-control study. Leukemia 2005; 19: 1912-1918.
8. Lee JH, Shin YR, Lee JS, et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 2003; 17: 305-313.
9. Intragumtornchai T, Prayoonwiwat W, Swasdikul D, et al. Myelodysplastic syndromes in Thailand: A retrospective pathologic and clinical analysis of 117 cases. Leuk Res 1998; 22: 453-460.
10. Chen B, Zhao WL, Jin J, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 2005; 19: 767-775.
11. Nosslinger T, Reisner R, Koller E, et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: Comparison of classifications on 431 unselected patients from a single institution. Blood 2001; 98: 2935-2941.
12. Matsuda A, Germing U, Jinnai I, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 2005; 106: 2633-2640.
13. Kuendgen A, Matsuda A, Germing U. Differences in epidemiology of MDS between Western and Eastern countries: Ethnic differences or environmental influence? Leuk Res 2007; 31: 103-104.
14. Attia SM. Chromosomal composition of micronuclei in mouse bone marrow treated with rifampicin and nicotine, analyzed by multicolor fluorescence in situ hybridization with pancentromeric DNA probe. Toxicology 2007; 235: 112-118.
15. Holdiness MR. A review of blood dyscrasias induced by the antituberculosis drugs. Tubercle 1987; 68: 301-309.
16. Rac VV, Gupta EV, Thomas IM. Chromosomal aberrations in tuberculosis patients before and after treatment with short-term chemotherapy. Mutat Res 1991; 259: 13-19.
17. Jaju M, Ahuja YR. Cytogenetic effects of chemotherapy with three combinations of anti-tubercular drugs involving isoniazid, thiacetazone, para-aminosalicylic acid and streptomycin on human lymphocytes: Chromosome aberrations, sister chromatid exchanges and mitotic index. Hum Genet 1983; 64: 42-49.
18. Brugnone F, Perbellini L, Maranelli G, et al. [Effects of cigarette smoking on blood and alveolar air levels of benzene]. Med Lav 1990; 81: 101-106.
19. Brownson RC, Novotny TE, Perry MC. Cigarette smoking and adult leukemia. A meta-analysis. Arch Intern Med 1993; 153: 469-475.
20. Du Y, Fryzek J, Sekeres MA, et al. Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS). Leuk Res 2010; 34: 1-5.
21. Pekmezovic T, Suvajdzic Vukovic N, Kisic D, et al. A case-control study of myelodysplastic syndromes in Belgrade (Serbia Montenegro). Ann Hematol 2006; 85: 514-519.
22. Ido M, Nagata C, Kawakami N, et al. A case-control study of myelodysplastic syndromes among Japanese men and women. Leuk Res 1996; 20: 727-731.
23. Rana SV, Verma Y. Biochemical toxicity of benzene. J Environ Biol 2005; 26: 157-168.
24. Vigliani EC, Saita G. Benzene and leukemia. N Engl J Med 1964; 271: 872-876.
25. Aksoy M, Dincol K, Erdem S, et al. Acute leukemia due to chronic exposure to benzene. Am J Med 1972; 52: 160-166.
26. Steensma DP. Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguity. Leuk Res 2006; 30: 1227-1233.
27. Rigolin GM, Cuneo A, Roberti MG, et al. Exposure to myelotoxic agents and myelodysplasia: Case-control study and correlation with clinicobiological findings. Br J Haematol 1998; 103: 189-197.
28. Hayes RB, Yin SN, Dosemeci M, et al. Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine-National Cancer Institute Benzene Study Group. J Natl Cancer Inst 1997; 89: 1065-1071.
29. Natelson EA. Benzene exposure and refractory sideroblastic erythropoiesis: Is there an association? Am J Med Sci 2007; 334: 356-360.
30. Rinsky RA, Young RJ, Smith AB. Leukemia in benzene workers. Am J Ind Med 1981; 2: 217-245.
31. Liu H, Liang Y, Bowes S, et al. Benzene exposure in industries using or manufacturing paint in China-A literature review, 1956-2005. J Occup Environ Hyg 2009; 6: 659-670.
32. Mehlman MA. Dangerous and cancer-causing properties of products and chemicals in the oil-refining and petrochemical industry, Part 22: Health hazards from exposure to gasoline containing methyl tertiary butyl ether: Study of New Jersey residents. Toxicol Ind Health 1996; 12: 613-627.
33. Paz-y-Mino C, Lopez-Cortes A, Arevalo M, et al. Monitoring of DNA damage in individuals exposed to petroleum hydrocarbons in Ecuador. Ann NY Acad Sci 2008; 1140: 121-128.
34. Jamall IS, Willhite CC. Is benzene exposure from gasoline carcinogenic? J Environ Monit 2008; 10: 176-187.
35. McCraw DS, Joyner RE, Cole P. Excess leukemia in a refinery population. J Occup Med 1985; 27: 220-222.
36. Raaschou-Nielsen O, Obel J, Dalton S, et al. Socioeconomic status and risk of childhood leukaemia in Denmark. Scand J Public Health 2004; 32: 279-286.
37. Alston RD, Rowan S, Eden TO, et al. Cancer incidence patterns by region and socioeconomic deprivation in teenagers and young adults in England. Br J Cancer 2007; 96: 1760-1766.
38. Lynch J, Kaplan G. Social Epidemiology. Oxford University Press; Oxford 2000.
39. Dalamaga M, Petridou E, Cook FE, et al. Risk factors for myelodysplastic syndromes: A case-control study in Greece. Cancer Causes Control 2002; 13: 603-608.
40. Ames BN, Kammen HO, Yamasaki E. Hair dyes are mutagenic: Identification of a variety of mutagenic ingredients. Proc Natl Acad Sci USA 1975; 72: 2423-2427.
41. Rollison DE, Helzlsouer KJ, Pinney SM. Personal hair dye use and cancer: A systematic literature review and evaluation of exposure assessment in studies published since 1992. J Toxicol Environ Health B Crit Rev 2006; 9: 413-439.
42. Correa A, Mohan A, Jackson L, et al. Use of hair dyes, hematopoietic neoplasms, and lymphomas: A literature review. I. Leukemias and myelodysplastic syndromes. Cancer Invest 2000; 18: 366-380.
43. Thun MJ, Altekruse SF, Namboodiri MM, et al. Hair dye use and risk of fatal cancers in U.S. women. J Natl Cancer Inst 1994; 86: 210-215.
44. Chen YL, Sha CX, Zhang J, et al. An investigation of indoor air pollution of organic chemicals. Chin J Health Inspect 2002; 9: 84-86.
45. Ling YC, Wang ZQ, Wang ZH. Analysis of organic chemicals of indoor airs in newly renovated homes. Chin J Health Lab Tech 2000; 10: 556-557.
46. Yuan H, Yao Y, Jin Y. Logsitic regression analysis on risk factors of acute leukemia. Chin J Public Health 2004; 20: 1328-1329.
47. Wang J, Jia H. Analysis of environmental risk factors of acute leukemia. Modern Prenet Med 2006; 33: 809-810.
48. Ma R. Treatment of bone marrow failure syndrome with integrated traditional and Western medicine. Chin J Integr Med 2007; 13: 85-88.